No significant direct pharmacokinetic interactions have been identified between GLP-1 medications (semaglutide, tirzepatide) and ADHD stimulant medications (amphetamines, methylphenidate). However, important clinical considerations apply: (1) Additive appetite suppression — ADHD stimulants are anorectic; combined with GLP-1's appetite suppression, patients may experience significant undernutrition; (2) Both affect the dopaminergic reward system — though through different mechanisms; (3) GLP-1 slows gastric emptying, which could delay absorption and alter peak effect timing of oral stimulants; (4) Cardiovascular monitoring — stimulants raise heart rate and blood pressure; GLP-1 mildly reduces blood pressure; in patients with cardiac history, co-prescribing requires cardiology awareness.

Yes — both GLP-1 medications and stimulants (amphetamine salts, methylphenidate) suppress appetite, and the effects are additive. Stimulant-related appetite suppression is a known concern in ADHD treatment, particularly in children; in adults, stimulant-induced weight loss is well documented. Combining GLP-1 with stimulants significantly increases the risk of: caloric intake falling below minimum health requirements (~1,200 kcal/day for most adults), protein inadequacy leading to muscle mass loss, micronutrient deficiencies, and excessive weight loss (past goal). Patients on both should proactively track caloric and protein intake and discuss minimum intake targets with their provider. Some patients may need to use GLP-1 at a lower effective dose when on stimulants.

GLP-1 and ADHD share interesting mechanistic overlap. GLP-1 receptors are expressed in prefrontal cortex, striatum, and dopaminergic pathways relevant to ADHD. Observational reports and patient communities describe both positive and negative cognitive experiences on GLP-1: Reported improvements: reduced impulsive eating (relevant for ADHD-associated impulsive food behavior), improved executive function secondary to better sleep and reduced brain inflammation, anecdotal reduction in 'decision fatigue' around food. Reported challenges: 'brain fog' in some patients during early treatment, which may interact with ADHD cognitive symptoms. No randomized trial has evaluated GLP-1 for ADHD symptom management specifically. GLP-1 does not replace stimulant therapy for ADHD.

ADHD and obesity are significantly comorbid — adults with ADHD have approximately 2x higher obesity prevalence than adults without ADHD. Mechanisms: (1) Impulse control impairment — ADHD's executive function deficit promotes impulsive eating, difficulty resisting palatable foods, and binge eating; (2) Reward dysregulation — ADHD involves dopaminergic hypofunction in reward circuits; seeking highly palatable food compensates for reward pathway underactivation; (3) Time blindness and planning — meal skipping followed by overeating; poor meal prep consistency; (4) Sleep disruption — common in ADHD; poor sleep promotes weight gain; (5) Stimulant timing — appetite suppression during stimulant peak leads to insufficient daytime intake, followed by compensatory overeating in evenings when stimulants wear off. GLP-1 addresses reward drive and appetite through overlapping pathways — which is why it may be particularly effective in ADHD-associated obesity.

GLP-1's modulation of dopaminergic reward circuits may specifically address the ADHD-specific drivers of obesity. ADHD-related overeating is often driven by reward seeking and impulse control failure rather than caloric miscalculation — and these are exactly the mechanisms GLP-1 modulates through nucleus accumbens signaling. Reports from ADHD patients on GLP-1 commonly include: 'food stopped calling my name,' 'I can walk past the kitchen without being hijacked by cravings,' and 'I don't finish my plate anymore.' These descriptions parallel the 'food noise' reduction GLP-1 produces and suggest particular relevance for the impulsive, reward-driven eating pattern characteristic of ADHD obesity.